



Smart

PA

Clinical Edit Criteria

Drug/Drug Class: **Entresto® (sacubitril/valsartan) Clinical Edit**
 Date: **December 3, 2018**
 Prepared for: **MO HealthNet**
 Prepared by: **Conduent-Heritage**

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: To control costs by following evidence based medical guidelines to ensure appropriate use of Entresto®.

5.1 million lives in the US have heart failure and 1 in 9 deaths in 2009 included heart failure as a contributing cause. About half of the people who develop heart failure die within 5 years of diagnosis and heart failure costs the nation an estimated \$32 billion each year. The New York Heart Association (NYHA) have developed four classifications for heart failure:

Why was this Issue Selected:

- I. Cardiac disease, but no symptoms and no limitations in ordinary physical activity, e.g. no shortness of breath when walking, climbing stairs, etc.
- II. Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
- III. Marked limitation in activity due to symptoms, even less during less than ordinary activity, e.g. walking short distances (20-100 m).
- IV. Severe limitation, experiences symptoms even while at rest. Mostly bed bound patients.

Entresto® is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction and is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.

Program-specific information:	Drug	Claims	Spend
	<ul style="list-style-type: none"> Entresto® 	1,869	\$806,972.50

Setting & Population: All MO HealthNet Participants

Type of Criteria:

Increased risk of ADE Non-Preferred Agent

Appropriate Indications

Data Sources: Only administrative databases Databases + Prescriber-supplied

Setting & Population

- Drug class for review: Heart Failure
- Age range: All adult participants

Approval Criteria

- Diagnosis of heart failure classified as NYHA II, NYHA III or NYHA IV and
- Ejection Fraction less than or equal to 40%

Denial Criteria

- No trial and failure of an angiotensin converting enzyme inhibitor (ACE-I or angiotensin II receptor blockers (ARB)
- No covered diagnosis
- Ejection fraction > 40%